EXAS241220P55000
- 6.35
- 0.000.00%
Exact Sciences Newsroom
Exact Sciences Is Maintained at Overweight by Piper Sandler
Exact Sciences Analyst Ratings
Piper Sandler Maintains Exact Sciences(EXAS.US) With Buy Rating, Cuts Target Price to $75
Scotiabank Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $70
Exact Sciences (EXAS) Gets a Buy From Wells Fargo
Exact Sciences Is Maintained at Buy by Jefferies
Jefferies Maintains Buy on Exact Sciences, Raises Price Target to $85
Exact Sciences Price Target Cut to $60.00/Share From $80.00 by Evercore ISI Group
A Quick Look at Today's Ratings for Exact Sciences(EXAS.US), With a Forecast Between $75 to $85
Exact Sciences (EXAS) Gets a Buy From Benchmark Co.
Exact Sciences Is Maintained at Outperform by Baird
Exact Sciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Exact Sciences (EXAS) and Crispr Therapeutics AG (CRSP)
BTIG Keeps Their Buy Rating on Exact Sciences (EXAS)
Positive Long-Term Outlook for Exact Sciences: Buy Rating Despite Short-Term Challenges
Bernstein Maintains Outperform on Exact Sciences, Raises Price Target to $90
Exact Sciences Is Maintained at Buy by Canaccord Genuity
Exact Sciences Analyst Ratings
CCORF Maintains Exact Sciences(EXAS.US) With Buy Rating, Raises Target Price to $95
Leerink Partners Maintains Exact Sciences(EXAS.US) With Buy Rating